Aussie scientists develop blood test for bowel cancer
08 May, 2014 by Dylan Bushell-EmblingClinical Genomics and CSIRO have developed a DNA blood test for bowel cancer that has a detection rate of 65%, or 73% for cancers at stage II or higher.
Virax options biomarker for cancer treatment
06 May, 2014 by Dylan Bushell-EmblingVirax Holdings (ASX:VLA) has optioned a technology to identify patients most likely to benefit from GGTI-2418, a cancer treatment candidate it plans to acquire with the purchase of Pathway Oncology.
Stem cells repair injured heart
05 May, 2014Researchers have successfully used embryonic stem cell-derived heart muscle cells to repair injured primate hearts.
Biomedical engineering alliance
02 May, 2014A biomedical engineering alliance strengthens the partnership between the University of Sydney and Shanghai Jiaotong University.
MiReven nabs US patent for anticancer technology
01 May, 2014 by Dylan Bushell-EmblingMiReven has picked up its first US patent for the microRNA precursor based anticancer technology developed by the Harry Perkins Institute of Medical Research.
The microRNA perspective
30 April, 2014 by Susan WilliamsonThe persistently high blood glucose levels associated with diabetes can, over time, cause damage to blood vessels that result in so-called diabetes-related complications. Preventing or reducing diabetes-related complications in the kidney is the focus of some of the work currently underway at the Baker IDI.
Cochlea implant delivers gene therapy
29 April, 2014Electrical pulses delivered from a cochlear implant have been used to deliver gene therapy and succesfully regrow auditory nerves.
Prima starts recruiting for ovarian cancer trial
28 April, 2014 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has signed up the first patient for CAN-004, its phase II trial of therapy candidate CVac in epithelial ovarian cancer.
CNS to help plan pancreatic cancer trial
22 April, 2014 by Dylan Bushell-EmblingCNS has secured a deal to provide clinical and regulatory services for a Nuvilex pancreatic cancer treatment candidate, including planning for an Australian phase IIb trial.
Funding for prostate cancer research
22 April, 2014Funding is available for translational research in prostate cancer.
The evolution of chloroquine
17 April, 2014A different way of administering chloroquine could see its renewed use to treat malaria.
Innate to start recruiting for SPMS trial in June
16 April, 2014 by Dylan Bushell-EmblingInnate Immunotherapeutics (ASX:IIL) expects to start recruiting up to 90 secondary progressive multiple sclerosis patients for a phase IIb trial of MIS416 in June.
BioProspect to acquire mental illness test
14 April, 2014 by Dylan Bushell-EmblingBioProspect (ASX:BPO) will acquire a stake in Invatec and a global licence to a potential heart rate-based diagnostics test for a wide range of mental health disorders.
Burnet research and development agreement with China
14 April, 2014The Burnet Institute has signed a $5 million agreement with China to support the development of low-cost diagnostic tests.
Starpharma secures expanded deal with AstraZeneca
11 April, 2014 by Dylan Bushell-EmblingAstraZeneca has arranged to evaluate using Starpharma's DEP dendrimer drug delivery technology for a second cancer drug.
